Tirzepatide

Dual GLP-1 / GIP agonist with the strongest weight-loss data in trials to date.

Typical dose range: 2.5–15 mg

Frequency: Weekly

Route: Subcutaneous

Half-life: ~5 days

Evidence level: Strong (FDA-approved)

Overview

Marketed as Mounjaro and Zepbound. Outperforms semaglutide head-to-head in most trials. Standard titration is 4-week jumps to limit nausea.